Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
Recommendation is based on pivotal data from the phase III POLARIX study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
